secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0000950170-25-035909
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Q4 2024 net loss $13.7M; cash $245.5M; FA and FECD trials advancing
--------------------------------------------------------------------------------

- Net loss of $13.7M for Q4 2024 and $49.6M for full year 2024; R&D expense $44.4M, G&A $18.0M.
- Cash, equivalents and securities $245.5M as of Dec 31, 2024; expected funding into 2029.
- FA program: Phase 1 single ascending dose trial of DT-216P2 initiated; patient dosing expected mid-2025.
- FECD program: DT-168 Phase 1 dosing complete; data on track for H1 2025; observational study enrolled ~250 patients.
- DM1 development candidate selection expected in 2025; HD preclinical work ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017025035909/0000950170-25-035909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017025035909/dsgn-20250310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-035909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer